Endometrial Cancer – Vistusertib Plus Arimidex in Patients With HR+
Importance Endometrial cancer is often hormone-dependent and treated with aromatase inhibitors, (AIs). The uncontrolled PI3K-AKT-mTOR pathway observed in this type of cancer drives hormonal resistance. Therefore, there is rationale of…